FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001699741> ?p ?o ?g. }

• W2001699741 endingPage "814" @default.
• W2001699741 startingPage "807" @default.
• W2001699741 abstract "Background and Objective The influence of glycemic control on cardiovascular (CV) complications or survival is not clear in diabetic patients with end-stage renal disease (ESRD). Although glycohemoglobin (HbA1c) is widely used as a marker of hyperglycemia in these patients, it may be unreliable because of shortened erythrocyte lifespan. Glycated albumin (GA) is an alternative marker. We investigated the relation between these markers and development of CV complications or survival in diabetic ESRD patients. Patients and Methods We obtained three variables as markers of glycemic control: 1) mean HbA1c levels during 1-year after initiation of dialysis (HbA1c1), 2) mean HbA1c levels during 3 months from August to October 2002 (HbA1c2), 3) GA on October 2002 (GA2) from 78 type 2 diabetic patients on chronic hemodialysis. We examined the influence of these variables on survival or development of CV diseases using the multivariate Cox proportional-hazards models until September 2006. Results The 3-year survival rate was 73%. A total of 27 patients died, 15 from CV diseases. A total of 23 CV diseases developed in 20 patients. Neither HbA1c1nor HbA1c2 was associated with all-cause mortality, CV mortality or development of CV diseases. GA2 was also not associated with mortality. However, the higher GA2 group (GA ≥ 23.0%) had a significantly higher rate of development of CV diseases than the lower GA2 group (GA < 23.0%) (log-rank test p=0.03). The higher GA2 group was significantly associated with development of CV diseases relative to the lower GA2 group (hazard ratio 3.25, p=0.04). Conclusion Neither HbA1c levels nor GA levels, at initiation of dialysis or on chronic dialysis, predicted mortality in diabetic ESRD patients. However, poor glycemic control as reflected by higher GA levels may be associated with the development of CV diseases. More studies are needed to clarify the beneficial effect of glycemic control in these patients." @default.
• W2001699741 created "2016-06-24" @default.
• W2001699741 creator A5006911614 @default.
• W2001699741 creator A5021908162 @default.
• W2001699741 creator A5032930623 @default.
• W2001699741 creator A5041415582 @default.
• W2001699741 creator A5062776469 @default.
• W2001699741 creator A5065084665 @default.
• W2001699741 creator A5089882625 @default.
• W2001699741 date "2007-01-01" @default.
• W2001699741 modified "2023-10-10" @default.
• W2001699741 title "Association between Markers of Glycemic Control, Cardiovascular Complications and Survival in Type 2 Diabetic Patients with End-Stage Renal Disease" @default.
• W2001699741 cites W1752045965 @default.
• W2001699741 cites W1972213378 @default.
• W2001699741 cites W1980947092 @default.
• W2001699741 cites W1991663574 @default.
• W2001699741 cites W1992605089 @default.
• W2001699741 cites W2010001751 @default.
• W2001699741 cites W2014929553 @default.
• W2001699741 cites W2020895356 @default.
• W2001699741 cites W2022119612 @default.
• W2001699741 cites W2035844132 @default.
• W2001699741 cites W2041809539 @default.
• W2001699741 cites W2042464606 @default.
• W2001699741 cites W2052006031 @default.
• W2001699741 cites W2057651652 @default.
• W2001699741 cites W2069405145 @default.
• W2001699741 cites W2072636048 @default.
• W2001699741 cites W2072794138 @default.
• W2001699741 cites W2078089300 @default.
• W2001699741 cites W2078944084 @default.
• W2001699741 cites W2080352318 @default.
• W2001699741 cites W2096315962 @default.
• W2001699741 cites W2113459904 @default.
• W2001699741 cites W2114054646 @default.
• W2001699741 cites W2120704605 @default.
• W2001699741 cites W2120733514 @default.
• W2001699741 cites W2123946565 @default.
• W2001699741 cites W2139634859 @default.
• W2001699741 cites W2148752381 @default.
• W2001699741 cites W2150635730 @default.
• W2001699741 cites W2168205528 @default.
• W2001699741 cites W2769264260 @default.
• W2001699741 cites W4229984599 @default.
• W2001699741 cites W4241798366 @default.
• W2001699741 cites W2071410768 @default.
• W2001699741 doi "https://doi.org/10.2169/internalmedicine.46.6355" @default.
• W2001699741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17575371" @default.
• W2001699741 hasPublicationYear "2007" @default.
• W2001699741 type Work @default.
• W2001699741 sameAs 2001699741 @default.
• W2001699741 citedByCount "75" @default.
• W2001699741 countsByYear W20016997412012 @default.
• W2001699741 countsByYear W20016997412013 @default.
• W2001699741 countsByYear W20016997412014 @default.
• W2001699741 countsByYear W20016997412015 @default.
• W2001699741 countsByYear W20016997412016 @default.
• W2001699741 countsByYear W20016997412017 @default.
• W2001699741 countsByYear W20016997412018 @default.
• W2001699741 countsByYear W20016997412019 @default.
• W2001699741 countsByYear W20016997412020 @default.
• W2001699741 countsByYear W20016997412022 @default.
• W2001699741 countsByYear W20016997412023 @default.
• W2001699741 crossrefType "journal-article" @default.
• W2001699741 hasAuthorship W2001699741A5006911614 @default.
• W2001699741 hasAuthorship W2001699741A5021908162 @default.
• W2001699741 hasAuthorship W2001699741A5032930623 @default.
• W2001699741 hasAuthorship W2001699741A5041415582 @default.
• W2001699741 hasAuthorship W2001699741A5062776469 @default.
• W2001699741 hasAuthorship W2001699741A5065084665 @default.
• W2001699741 hasAuthorship W2001699741A5089882625 @default.
• W2001699741 hasBestOaLocation W20016997411 @default.
• W2001699741 hasConcept C126322002 @default.
• W2001699741 hasConcept C134018914 @default.
• W2001699741 hasConcept C207103383 @default.
• W2001699741 hasConcept C2778063415 @default.
• W2001699741 hasConcept C2779056158 @default.
• W2001699741 hasConcept C2779134260 @default.
• W2001699741 hasConcept C2779306644 @default.
• W2001699741 hasConcept C2779978075 @default.
• W2001699741 hasConcept C2780473172 @default.
• W2001699741 hasConcept C3019040382 @default.
• W2001699741 hasConcept C44249647 @default.
• W2001699741 hasConcept C50382708 @default.
• W2001699741 hasConcept C555293320 @default.
• W2001699741 hasConcept C71924100 @default.
• W2001699741 hasConcept C90924648 @default.
• W2001699741 hasConceptScore W2001699741C126322002 @default.
• W2001699741 hasConceptScore W2001699741C134018914 @default.
• W2001699741 hasConceptScore W2001699741C207103383 @default.
• W2001699741 hasConceptScore W2001699741C2778063415 @default.
• W2001699741 hasConceptScore W2001699741C2779056158 @default.
• W2001699741 hasConceptScore W2001699741C2779134260 @default.
• W2001699741 hasConceptScore W2001699741C2779306644 @default.
• W2001699741 hasConceptScore W2001699741C2779978075 @default.
• W2001699741 hasConceptScore W2001699741C2780473172 @default.
• W2001699741 hasConceptScore W2001699741C3019040382 @default.
• W2001699741 hasConceptScore W2001699741C44249647 @default.

• next